Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.

[1]  S. Shin,et al.  Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. , 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[2]  C. Ki,et al.  Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease , 2018, American journal of respiratory and critical care medicine.

[3]  D. Hansell,et al.  Whole‐Blood Gene Expression in Pulmonary Nontuberculous Mycobacterial Infection , 2017, American journal of respiratory cell and molecular biology.

[4]  W. Hoefsloot,et al.  Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. , 2017, Respiratory medicine.

[5]  C. Haworth,et al.  British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) , 2017, BMJ Open Respiratory Research.

[6]  Chong-Jen Yu,et al.  Microbiological Persistence in Patients With Mycobacterium avium Complex Lung Disease: The Predictors and the Impact on Radiographic Progression , 2017, Clinical Infectious Diseases.

[7]  C. Ki,et al.  Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype , 2017, European Respiratory Journal.

[8]  K. Winthrop,et al.  Long‐Term Outcomes in a Population‐based Cohort with Respiratory Nontuberculous Mycobacteria Isolation , 2017, Annals of the American Thoracic Society.

[9]  C. Ki,et al.  Distribution and clinical significance of Mycobacterium avium complex species isolated from respiratory specimens. , 2017, Diagnostic microbiology and infectious disease.

[10]  S. Madhi,et al.  Safety of Induced Sputum Collection in Children Hospitalized With Severe or Very Severe Pneumonia , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  T. Shim,et al.  Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course , 2017, European Respiratory Journal.

[12]  J. Yim,et al.  Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Yong Soo Choi,et al.  Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Yim,et al.  Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : a prospective cohort study , 2017, BMC Pulmonary Medicine.

[15]  S. Tomida,et al.  Comparative genome analyses of Mycobacterium avium reveal genomic features of its subspecies and strains that cause progression of pulmonary disease , 2017, Scientific Reports.

[16]  C. Ki,et al.  Clinical characteristics and treatment outcomes of pulmonary disease caused by Mycobacterium chimaera. , 2016, Diagnostic microbiology and infectious disease.

[17]  Chang Ki Kim,et al.  Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. , 2016, Chest.

[18]  C. Qi,et al.  Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility. , 2016, Annals of the American Thoracic Society.

[19]  J. Stout,et al.  Update on pulmonary disease due to non-tuberculous mycobacteria. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[20]  Charles L Daley,et al.  Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives , 2016, Tuberculosis and respiratory diseases.

[21]  Jae Ho Lee,et al.  Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  T. Kanauchi,et al.  Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease , 2015, BMJ Open.

[23]  C. Qi,et al.  Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species. , 2015, American journal of respiratory and critical care medicine.

[24]  R. Wallace,,et al.  The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy. , 2015, Chest.

[25]  T. Shim,et al.  Risk Factors for Recurrence after Successful Treatment of Mycobacterium avium Complex Lung Disease , 2015, Antimicrobial Agents and Chemotherapy.

[26]  E. Chan,et al.  Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. , 2015, Clinics in chest medicine.

[27]  D. R. Prevots,et al.  Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. , 2015, Clinics in chest medicine.

[28]  J. Philley,et al.  Treatment of slowly growing mycobacteria. , 2015, Clinics in chest medicine.

[29]  T. Shim,et al.  A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. , 2014, Respiratory medicine.

[30]  J. Stout,et al.  Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[31]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.

[32]  I. Orme,et al.  Host Response to Nontuberculous Mycobacterial Infections of Current Clinical Importance , 2014, Infection and Immunity.

[33]  H. Yoon,et al.  Risk factors for deterioration of nodular bronchiectatic Mycobacterium avium complex lung disease. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[34]  K. Lee,et al.  Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. , 2013, Annals of the American Thoracic Society.

[35]  Sang-Nae Cho,et al.  Mycobacterial genotypes are associated with clinical manifestation and progression of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  E. Chan,et al.  Underlying Host Risk Factors for Nontuberculous Mycobacterial Lung Disease , 2013, Seminars in Respiratory and Critical Care Medicine.

[37]  T. Kanauchi,et al.  Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.

[38]  K. Lee,et al.  Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. , 2012, Chest.

[39]  T. Iwamoto,et al.  Clinical and Microbiological Differences between Mycobacterium abscessus and Mycobacterium massiliense Lung Diseases , 2012, Journal of Clinical Microbiology.

[40]  K. Matsuura,et al.  Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[41]  Pan‐Chyr Yang,et al.  Risk factors for Mycobacterium chelonae-abscessus pulmonary disease persistence and deterioration. , 2012, The Journal of infection.

[42]  Brian G. Williams,et al.  Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review , 2011, PloS one.

[43]  Young Kil Park,et al.  Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.

[44]  M. Ebina,et al.  Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection , 2009, Thorax.

[45]  W. Yew,et al.  When and how to treat pulmonary non‐tuberculous mycobacterial diseases , 2009, Respirology.

[46]  N. Ampel.  Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases , 2007 .

[47]  Lloyd N. Friedman,et al.  Diagnostic standards and classification of tuberculosis. , 1991, The American review of respiratory disease.

[48]  R. Wallace,,et al.  Diagnosis and treatment of disease caused by nontuberculous mycobacteria. , 1990, The American review of respiratory disease.

[49]  C. Ki,et al.  Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. , 2015, American journal of respiratory and critical care medicine.

[50]  Tuberculosis in a rural population of South India: a five-year epidemiological study. , 1974, Bulletin of the World Health Organization.